Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a sub-study of belantamab mafodotin in combination with isatuximab for relapsed/refractory multiple myeloma (Phase 1/Phase 2). The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• SARCLISA (isatuximab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING